Search Results - "Hillner, B"

Ensuring Quality Cancer Care by the Use of Clinical Practice Guidelines and Critical Pathways by SMITH, Thomas J, HILLNER, Bruce E

“…We describe the impact of clinical practice guidelines (CPGs) on improvement in oncology treatment processes or outcomes. We performed a comprehensive search…”
Get full text

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America by Antman, K H, Rowlings, P A, Vaughan, W P, Pelz, C J, Fay, J W, Fields, K K, Freytes, C O, Gale, R P, Hillner, B E, Holland, H K, Kennedy, M J, Klein, J P, Lazarus, H M, McCarthy, Jr, P L, Saez, R, Spitzer, G, Stadtmauer, E A, Williams, S F, Wolff, S, Sobocinski, K A, Armitage, J O, Horowitz, M M

“…To identify trends in high-dose therapy with autologous hematopoietic stem-cell support (autotransplants) for breast cancer (1989 to 1995). Analysis of…”
Get more information

Hospital and Physician Volume or Specialization and Outcomes in Cancer Treatment: Importance in Quality of Cancer Care by Hillner, B E, Smith, T J, Desch, C E

“…To conduct a comprehensive review of the health services literature to search for evidence that hospital or physician volume or specialty affects the outcome…”
Get full text

Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis by HILLNER, B. E, WEEKS, J. C, DESCH, C. E, SMITH, T. J

“…Pamidronate is effective in reducing bony complications in patients with metastatic breast cancer who have known osteolytic lesions. However, pamidronate does…”
Get full text

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma by Smith, T J, Hillner, B E, Schmitz, N, Linch, D C, Dreger, P, Goldstone, A H, Boogaerts, M A, Ferrant, A, Link, H, Zander, A, Yanovich, S, Kitchin, R, Erder, M H

“…High-dose chemotherapy (HDC) with peripheral-blood progenitor cell (PBPC) and autologous bone marrow (ABM) transplant (T) has documented survival benefits for…”
Get more information

Current practice of temporary vena cava filter insertion: a multicenter registry by Lorch, H, Welger, D, Wagner, V, Hillner, B, Strecker, E P, Herrmann, H, Voshage, G, Zur, C, Schwarzbach, C, Schröder, J, Gullotta, U, Pleissner, J, Huttner, S, Siering, U, Märcklin, C, Chavan, A, Gläser, F, Apitzsch, D E, Moubayed, K, Leonhardi, J, Schuchard, U M, Weiss, H D, Zwaan, M

“…To evaluate the current practice of temporary vena cava filter placement and its complications. A multicenter registry was conducted from May 1995 until May…”
Get more information

The National Oncologic PET Registry (NOPR): Design and Analysis Plan by Hillner, Bruce E, Liu, Dawei, Coleman, R. Edward, Shields, Anthony F, Gareen, Ilana F, Hanna, Lucy, Stine, Sharon Hartson, Siegel, Barry A

“…The Centers for Medicare and Medicaid Services (CMS) has provided a mechanism for expanded coverage of selected promising technologies under its "coverage with…”
Get full text

Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer by Hayman, J A, Hillner, B E, Harris, J R, Weeks, J C

“…To examine the cost-effectiveness of radiation therapy following conservative surgery for early-stage breast cancer. Using a Markov model, a cost-utility…”
Get more information

Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis by Smith, T J, Hillner, B E, Desch, C E

Get more information

American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer by HILLNER, B. E, INGLE, J. N, BERENSON, J. R, JANJAN, N. A, ALBAIN, K. S, LIPTON, A, YEE, G, BIERMANN, J. S, CHLEBOWSKI, R. T, PFISTER, D. G

“…PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of bone metastases in breast cancer and their…”
Get full text

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684 by Hillner, B E, Kirkwood, J M, Atkins, M B, Johnson, E R, Smith, T J

“…Interferon alfa-2b (IFN) in a randomized clinical trial (E1684) prolonged relapse-free and total survival in high-risk resected melanoma. However, the costs…”
Get more information

Differences in initial treatment patterns and outcomes of lung cancer in the elderly by Smith, Thomas J., Penberthy, Lynne, Desch, Christopher E., Whittemore, Martha, Newschaffer, Craig, Hillner, Bruce E., McClish, Donna, Retchin, Sheldon M.

“…Background: Non-small cell lung cancer (NSCLC) accounts for substantial deaths and costs in the elderly greater than 65 years old. The current practice of…”
Get full text

Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer: A Decision-Analysis Model by Hillner, Bruce E, Smith, Thomas J

“…IN 1990 breast cancer affected more than 150,000 women in the United States; it will eventually be the cause of death of 25 percent of them. 1 The 1985…”
Get full text

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer by Smith, T J, Hillner, B E, Neighbors, D M, McSorley, P A, Le Chevalier, T

“…To estimate the comparative cost-effectiveness of three regimens for metastatic non-small-cell lung cancer (NSCLC). Results from a randomized clinical trial of…”
Get more information

A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery by Desch, Christopher E., Penberthy, Lynne T., Hillner, Bruce E., McDonald, M.Kathleen, Smith, Thomas J., Pozez, Andrea L., Retchin, Sheldon M.

“…Background: There are a variety of surgical choices for women with early-stage breast cancer, including breast-conserving surgery, mastectomy, or mastectomy…”
Get full text

Measuring standards of care for early breast cancer in an insured population by Hillner, B E, McDonald, M K, Penberthy, L, Desch, C E, Smith, T J, Maddux, P, Glasheen, W P, Retchin, S M

“…To demonstrate the use of a combined data base to evaluate the care for local/regional invasive breast cancer in a large insured population of women aged less…”
Get more information

Costs of care associated with non-small-cell lung cancer in a commercially insured cohort by Hillner, B E, McDonald, M K, Desch, C E, Smith, T J, Penberthy, L T, Maddox, P, Retchin, S M

“…To examine the cost of incident cases of non-small-cell lung cancer (NSCLC) in a commercially insured cohort. Claims from Virginia Blue Cross and Blue Shield…”
Get more information

Clinical Decisions Associated With Positron Emission Tomography in a Prospective Cohort of Patients With Suspected or Known Cancer at One United States Center by HILLNER, Bruce E, TUNUGUNTLA, Renuka, FRATKIN, Melvin

“…In 2001, Medicare approved reimbursement of F-18 fluorodeoxyglucose positron emission tomography (PET) for a variety of cancers. PET has been observed to be…”
Get full text

Tamoxifen Should be Cost-Effective in Reducing Breast Cancer Risk in High-Risk Women by SMITH, T. J, HILLNER, B. E

“…To estimate the cost-effectiveness of tamoxifen in the prevention of breast cancer. Clinical trial results of National Surgical Adjuvant Breast Program P-1…”
Get full text

Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma by Hillner, B.E

“…The use of interferon alfa-2b (IFN-α2b) as adjuvant therapy of high-risk resected cutaneous melanoma was recently found to significantly improve relapse-free…”
Get full text